Pfizer Acquires Amplyx Pharmaceuticals
网页2021年4月28日 · Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections. More than 1.5 million cases of invasive fungal infections occur worldwide each year, with mortality rates as high as 30-80% across infection types i.
Amplyx, now a subsidiary of Pfizer Inc. | LinkedIn
网页Amplyx was founded on a mission to save lives by developing a new class of antifungal medicine that would overcome the severe limitations of today’s therapeutic options.
Pfizer Inc. Logo & Brand Assets (SVG, PNG and vector) - Brandfetch
网页Find the Pfizer Inc. style guide with brand assets such as logos, colors, fonts, and more.
Amplyx Pharmaceuticals - Craft
网页Amplyx Pharmaceuticals is a pharmaceutical company focusing on the development of small molecule drugs, broad-spectrum antifungal agents for the treatment of life-threatening invasive fungal infections due to candida, aspergillus and rare molduls.
Pfizer Buys Amplyx Pharmaceuticals For Undisclosed Terms
网页2021年4月28日 · (RTTNews) - Pfizer Inc. (PFE) has acquired privately held Amplyx Pharmaceuticals, Inc., the company announced in a release. The acquisition, financial terms of which are not disclosed, follows an...
Amplyx Pharmaceuticals - Crunchbase Company Profile & Funding
网页Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect …
Pfizer buys Amplyx to expand drug-resistant treatment portfolio
网页CHICAGO, April 28 (Reuters) - Pfizer Inc (PFE.N) on Wednesday said it has acquired privately-held Amplyx Pharmaceuticals, which is developing a new treatment for drug-resistant "superbug" fungal...
Pfizer acquires Amplyx Pharmaceuticals to advance anti-infectives …
网页2021年4月29日 · Pfizer has acquired US-based Amplyx Pharmaceuticals to advance its expertise in infectious disease and expand its anti-infectives pipeline. Amplyx focuses on developing treatments for life-threatening diseases that affect individuals with compromised immune systems.
Pfizer buys Amplyx to expand drug-resistant treatment portfolio
网页2021年4月28日 · CHICAGO (Reuters) - Pfizer Inc on Wednesday said it has acquired privately-held Amplyx Pharmaceuticals, which is developing a new treatment for drug-resistant "superbug" fungal infections in...
Homepage [www.amylyx.com]
网页Avexitide is a first-in-class GLP-1 receptor antagonist and FDA Breakthrough Therapy with highly statistically significant data and well-tolerated safety profile replicated across multiple clinical trials. Phase 3 program in avexitide in post-bariatric hypoglycemia (PBH) expected to begin in Q1 2025. LEARN MORE.
- 某些结果已被删除
跳至内容